ABVX (Abivax) ROE % Adjusted to Book Value : -58.23% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Abivax ROE % Adjusted to Book Value?

Abivax's ROE % for the quarter that ended in Dec. 2023 was -183.43%. Abivax's PB Ratio for the quarter that ended in Dec. 2023 was 3.15. Abivax's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -58.23%.

Abivax ROE % Adjusted to Book Value Historical Data

The historical data trend for Abivax's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax ROE % Adjusted to Book Value Chart

Abivax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-46.21

Abivax Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-58.23

Competitive Comparison of Abivax's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Abivax's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abivax's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abivax's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Abivax's ROE % Adjusted to Book Value falls into.

Abivax ROE % Adjusted to Book Value Calculation

Abivax's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-145.56%	/	3.15
	=	-46.21%

Abivax's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-183.43%	/	3.15
	=	-58.23%

Abivax ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Abivax's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Abivax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (NAS:ABVX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

AAVXF:USA 0RA9:UK ABVX:France 2X1:Germany

Address

7-11 boulevard Haussmann, Paris, FRA, 75009

Website

https://www.abivax.com

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.